Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1
(pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer.
Each cycle last 21-days. All subjects will receive pembrolizumab via IV on day 1, and
abraxane via IV on Day 1 and Day 8 of each cycle. Subjects may continue to receive the study
regimen until they experience disease progression or unacceptable toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center